Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Oncorus, Inc. ONCR
$0.32
+$0.01 (3.23%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
8843731.00000000
-
week52high
1.90
-
week52low
0.23
-
Revenue
0
-
P/E TTM
0
-
Beta
2.82230600
-
EPS
-2.97000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 11:00
Описание компании
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 15 июн 2022 г. | |
| Piper Sandler | Overweight | Overweight | 19 мая 2022 г. |
| HC Wainwright & Co. | Buy | 28 мар 2022 г. | |
| Maxim Group | Buy | 16 мар 2021 г. | |
| Piper Sandler | Overweight | 27 окт 2020 г. | |
| HC Wainwright & Co. | Neutral | Buy | 06 дек 2022 г. |
| Chardan Capital | Neutral | Buy | 01 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Flynn James E | D | 284697 | 15220 | 30 дек 2022 г. |
| Flynn James E | D | 1156308 | 61826 | 30 дек 2022 г. |
| Flynn James E | D | 1156309 | 61826 | 30 дек 2022 г. |
| Flynn James E | D | 299917 | 15538 | 29 дек 2022 г. |
| Flynn James E | D | 1218134 | 63108 | 29 дек 2022 г. |
| Flynn James E | D | 1218135 | 63107 | 29 дек 2022 г. |
| Flynn James E | D | 315455 | 6096 | 28 дек 2022 г. |
| Flynn James E | D | 1281242 | 24757 | 28 дек 2022 г. |
| Flynn James E | D | 321551 | 7136 | 27 дек 2022 г. |
| Flynn James E | D | 1305999 | 28977 | 27 дек 2022 г. |
Новостная лента
Oncorus to Participate in Upcoming Investor Conferences
GlobeNewsWire
23 ноя 2022 г. в 08:00
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences:
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
07 ноя 2022 г. в 13:34
Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Oncorus to Present at Chardan's 6th Annual Genetic Medicines Conference
GlobeNewsWire
26 сент 2022 г. в 07:00
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY.
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 07:00
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:00 a.m. ET in New York, NY.
Here's Why Oncorus, Inc. (ONCR) Looks Ripe for Bottom Fishing
Zacks Investment Research
13 июл 2022 г. в 11:32
After losing some value lately, a hammer chart pattern has been formed for Oncorus, Inc. (ONCR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.